poisar

Stock

Bolt Biotherapeutics, Inc. BOLT

$3.35+4.36%

Overview

BOLT market data

Price History

BOLT price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$17.85
Diluted earnings per share over the trailing twelve months.
Beta
0.97
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-455.2%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$3.13 – $7.20
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $6.2M · P/B 0.40 · P/S 0.95.

Company News

3 captured
Bolt Biotherapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.Benzinga · Aug 12, 2026, 3:17 PM
Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K EstimateBenzinga · Aug 11, 2026, 8:20 PM
Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22Benzinga · May 29, 2026, 12:33 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock